Genome Editing and Chimeric Antigen Receptors T Cell Therapy | ||
| Suez Canal University Medical Journal | ||
| Editorial, Volume 20, Issue 2, October 2017, Pages 122-127 PDF (819.83 K) | ||
| DOI: 10.21608/scumj.2017.43560 | ||
| Author | ||
| Ranya Hassan* | ||
| Clinical pathology Department, Faculty of Medicine, Suez Canal university, Egypt | ||
| Abstract | ||
| Recent advances in genome editing technologies have significantly enhanced making specific changes in the genomes of different types cells. Genetically engineered T cells, or the 'living drugs', is considered a new era in antitumor therapy. Current clinical trials using chimeric antigen receptors (CARs) T cells showed a promising result in patients with some intractable hematological malignancies. In this Review, some of the most recent advances in CAR T cell therapy are mentioned high lightening the use of genome editing in this field. | ||
| Keywords | ||
| CRISPR/Cas9; chimeric antigen receptor; T lymphocytes; gene therapy | ||
|
Statistics Article View: 231 PDF Download: 467 |
||
